C-19 shot studies used by HHS conducted in China

Latest Polls (view all)

Where do you stand on the Transgender Issue now that the issue has gotten to the overt point of the open celebration of this lifestyle choice, dictated by certain direct and explicit actions.

88.37% I do not approve of behavior that has within its expressed tenants policies that harm children.

10.47% I do support the Trans Community in all its many facets because diversity is at a premium in today's society.

1.16% What is a "Children's Drag Queen Story Hour?"

Click Here to Vote
86 Vote(s)

View all Polls

C-19 shot studies used by HHS conducted in China

Published: Tuesday, September 27th, 2022 @ 11:38 am
By: Countrygirl1411 ( More Entries )

Login to Send a Private Message to Countrygirl1411

Judicial Watch announced today that it received 115 pages of records from the Department of Health and Human Services (HHS) revealing previously redacted locations of COVID-19 vaccine testing facilities in Shanghai, China. The Food and Drug Administration (FDA) had claimed the name and location of the testing facilities were protected by the confidential commercial information exemption of the Freedom of Information Act (FOIA).

The newly unredacted documents reveal the following Pfizer/BioNTech COVID-19 vaccine studies’ locations:

A document with the filename, “ s_r_IND 19736 0 105 2.6.5 pharmkintabulated-summary” identifies all in vitro metabolic stability studies of ALC-0315 and ALC-0159 (synthetic lipids in the vaccines) were conducted at Medicilon Preclinical Research LLC, a testing facility located in Shanghai, China. Studies within this record indicate work was done in August 2020.
A document with the filename, “s_r_IND 19736-0-253 Section 2.6.5 pharmkintabulated-summary” identifies that all in vitro metabolic stability studies of ALC-0315 and ALC-0159 were conducted at Medicilon Preclinical Research LLC, a testing facility located in Shanghai, China. Studies within this record indicate work was done in August 2020.

Additionally, Study 18350 was conducted at a Charles River testing facility in Tranent, UK

A document with the filename, “s_pharmkin-tabulated-summary.pdf” notes that all in vitro metabolic stability studies of ALC-0315 and ALC-0159 were conducted at Medicilon Preclinical Research LLC, a testing facility located in “Shanghai, China.” Studies within this record indicate work was done in August 2020.

The document adds that Study 18350 was conducted at a Charles River testing facility in Tranent, UK.

A document titled “FINAL REPORT” with the filename, “s_r_185350.pdf” and the logo, “Charles River” lists the TESTING FACILITY as “Charles River Laboratories Edinburgh Ltd. Elphinstone Research Centre Tranent, East Lothian EH33 2NE, UK” Studies within this record indicate the work was conducted in July 2020.

https://www.judicialwatch.org/covid-vaccine-studies-conducted-in-china/

Go Back